Table 2.
Immune reaction | Mechanism | Clinical manifestations | Timing of reaction |
---|---|---|---|
Type I (IgE-mediated) | Drug-IgE complex binding to mast cells with release of histamine, inflammatory mediators | Anaphylaxis*, urticaria*, angioedema*, bronchospasm* | Minutes to hours after drug exposure |
Type II (cytotoxic) | Specific IgG or IgM antibodies directed at drug-hapten coated cells | Anemia, cytopenia, thrombocytopenia | Variable |
Type III (immune complex) | Tissue deposition of drug-antibody complexes with complement activation and inflammation | Serum sickness, vasculitis, fever, rash, arthralgia | 1 to 3 weeks after drug exposure |
Type IV (delayed, cell mediated) | MHC presentation of drug molecules to T cells with cytokine and inflammatory mediator release; may also be associated with activation and recruitment of eosinophils, monocytes, and neutrophils | Contact sensitivity Skin rashes, organ-tissue damage |
2 to 7 days after drug exposure |
IgE: immunoglobulin E; IgG: immunoglobulin G; IgM: immunoglobulin G; MHC: major histocompatibility complex
*These reactions may also be non-immunologically mediated.
Adapted from Riedl et al., 2003.6